CRBU vs NVS
CRBU: A clinical-stage CRISPR genome-editing company developing off-the-shelf allogeneic CAR-T cell therapies for hematologic cancers. NVS: Novartis is a leading global pharmaceutical company focused on discovering and developing innovative, high-efficacy medicines across oncology, immunology, and neuroscience.
Side-by-side fundamentals
| Metric | CRBU | NVS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $0.4812 | $143.11 | |
| Market cap | $52M | $227.4B | |
| P/E as of 2026-09-03 | n/a | 21.95 | |
| Net margin FY2025, SEC XBRL | -1327.4% | n/a | |
| Operating margin FY2025, SEC XBRL | -1329.4% | n/a | |
| ROE FY2025, SEC XBRL | -121.2% | +30.0% | NVS higher |
| ROA FY2025, SEC XBRL | -84.5% | +12.6% | NVS higher |
| Debt / equity as of 2026-09-03 | 0.00 | 1.18 | CRBU lower |
| Revenue growth (YoY) as of 2026-09-03 | +13.0% | +3.3% | CRBU higher |
| Revenue CAGR (3y) SEC XBRL | -7.0% | n/a | |
| Dividend yield as of 2026-09-03 | n/a | +3.4% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-03 | 1.79 | 0.23 | |
| 1-year return as of 2026-10-08 close | -82.0% | +8.2% | NVS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.